CONSTANT LEVERAGE LONG - UCB Stock

A6YFB

NLBNPNL1Q9N4

Real-time Euronext Paris 03:07:15 2024-05-16 am EDT
11.74 ^EUR	-1.39%

Current month	-5.92%
1 month	+9.27%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB - Acquisition of own shares	May. 13	AQ
UCB : Acquisition of own shares	May. 10	PU
UCB presents final open-label extension F data at International Child Neurology Congress Annual Meeting	May. 09	AQ
UCB : presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	May. 08	PU

More news

Quotes 5-day view

Date	Price	Change
24-05-16	11.74	-1.39%
24-05-15	11.91	+6.10%
24-05-14	11.22	-4.18%
24-05-13	11.72	-2.74%
24-05-10	12.04	+10.66%

Real-time Euronext Paris

Last update May 16, 2024 at 03:07 am EDT

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	UCB
Issuer	BNP Paribas
	A6YFB
ISIN	NLBNPNL1Q9N4
Date issued	2022-03-09
Maturity	Unlimited
Parity	1 : 1
Emission price	- €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	18.05 €
Lowest since issue	2.08 €
Spread	0.45 €
Spread %	3.70%

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

122.6 EUR

Average target price

125.5 EUR

Spread / Average Target

+2.40%

Consensus